// App-Quantinova.ai

OP046 : Long-term safety and efficacy of biolimus-eluting coronary stents in an unselected patient population: final 3-year report of the large, multicentre e-BioMatrix registry

Researchers

Presenter

  • Hildick-Smith D

Principal Investigators

  • Alhaddad I

  • Berland J

  • Yazdani A

  • Urban P

  • Eberli F

  • Iosseliani D

  • Kleber F

  • Menown I

  • Oldroyd K

  • Roffi M

  • Valdes M

  • Kalloudi E

Medical Centers

  • Craigavon Cardiac Centre, Craigavon, United Kingdom

  • Hospital Clinico Universitario Virgen de la Arrixaca, Murcia, Spain

  • Brighton and Sussex, Brighton, United Kingdom

  • Clinique Saint Hilaire, Rouen, France

  • Hopitaux Universitaires de Geneve, Geneva, Switzerland

  • Charite-University Medicine Berlin, Berlin, Germany

  • Biosensors International, Morges, Switzerland

  • Hopital de la Tour, Geneva, Switzerland

  • Golden Jubilee National Hospital, Clydebank, United Kingdom

  • The Jordan Cardiovascular Center, Amman, Jordan

  • Stadtspital Triemli, Zurich, Switzerland

Locations

  • Spain

  • Germany

  • United Kingdom

  • Switzerland

  • Jordan

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • Myocardial infarction

  • Angina

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • Umirolimus

  • Aspirin

  • Albyl-E

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved